How should Pharma respond to the changes to NHS specialised services?

What should Market Access teams be doing now in response to the changes to specialised commissioning?
In this clip, Malcolm Qualie (Former Medicines Lead for Specialised Services, NHS England) recommends:
➡️ Focusing on your pipeline, in particular on products that will be going through NICE in 2025/26
➡️ Identifying key ICB decision makers that you need to speak to
➡️ Exploring how your innovation impacts the whole pathway
Malcolm also points out that, once you have been through NICE, clinical effectiveness and cost effectiveness are almost a given. To make waves, you need to demonstrate how your innovation will have a wider impact and sell this additional benefit.
We can help you map your clinical pathway and identify where your product will deliver value for a challenged NHS. To explore this further with our experts, email [e-mail]
To watch the full webinar (broadcast in December 2023) on demand now, visit mtechaccess.co.uk/nhs-special...
#specialisedcommissioning #speccomm #specialisedservices #pathwaymapping #Pharma #medicines #medicaldevices #NHSfunding #NHSinsights #NHSWhispers